Fig. 4: Prevalence of pathway-level alterations is increased in tumors exposed to CDK4/6i. | npj Breast Cancer

Fig. 4: Prevalence of pathway-level alterations is increased in tumors exposed to CDK4/6i.

From: CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape

Fig. 4: Prevalence of pathway-level alterations is increased in tumors exposed to CDK4/6i.

a–d Distribution of the number of altered gene sets for pre- and post-treatment groups of the (a) AI, or b AI+CDK4/6i cohorts, as well as for the (c) pre-treatment and d post-treatment groups of AI-based cohorts. P-values based on a Kolmogorff-Smirnov test. e, f Distribution of the number of altered gene sets for the post-treatment samples of the (e) AI and f AI+CDK4/6i cohorts based on the 1L treatment duration prior to sample collection. g Distribution of the number of altered gene sets of samples collected after 2L or 3L based on treatment cohorts. P-value between samples exposed to CDK4/6i (left) or not (right) based on a Kolmogorff-Smirnov test.

Back to article page